“This new research is critical for improving the therapies available. By avoiding these bleeding complications, we could potentially make treatment available to all stroke sufferers,” says Dr Maclean, postdoctoral research officer in the Thrombosis Group at HRI.
Dr Maclean’s work will investigate the efficacy of an exciting new therapeutic target to safely inhibit platelets in stroke by using several innovative methods recently established with the Thrombosis Group. The techniques include a large artery model of ischaemic stroke Dr Maclean co-developed during her PhD studies, as well as a newly developed method to visualise real-time thrombolysis within a laboratory environment.
Dr Maclean completed her PhD with HRI in 2020 and continues her postdoctoral career with a focus on understanding blood clot development in stroke and investigating new thrombolytic drugs for vascular diseases.
